Navigation Links
Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
Date:12/15/2008

SAN DIEGO, Dec. 15 /PRNewswire/ -- Cylene Pharmaceuticals today announced the initiation of a Phase II clinical trial of quarfloxin (CX-3543) in patients with carcinoid/neuroendocrine tumors (C/NET), which are malignant cancers arising from neural crest cells.

"Quarfloxin (CX-3543) is a small molecule that disrupts a protein:rDNA complex that forms in the abnormal nucleoli of cancer cells, thereby selectively inducing apoptotic cell death in cancers," said Dr. William Rice, President and Chief Executive Officer of Cylene Pharmaceuticals. "Many commercialized cancer therapeutics act on or through the nucleolus, but quarfloxin is the first agent designed to directly target a key function within the nucleolus. Quarfloxin has been well tolerated in humans and has demonstrated signs of biological benefit for patients with C/NET in Phase I clinical trials. Moreover, biodistribution studies revealed that quarfloxin accumulates in the tissues in which C/NET arise."

In this open-label Phase II trial, quarfloxin will be administered to patients with low or intermediate grade C/NET, including those receiving concomitant treatment with a stable dose of octreotide. This multi-centered study will include an assessment of improvements in patients' symptoms and biochemical markers, in addition to RECIST tumor response measurements. The first patient was enrolled and treated at Front Range Cancer Specialists in Fort Collins, CO under the care of Robert Marschke Jr., M.D. This study is expected to enroll up to 25 patients at several leading cancer centers.

"The initiation of this Phase II trial with quarfloxin is a major milestone for Cylene, but more importantly, we hope that quarfloxin will be an effective treatment for cancer patients with limited therapeutic alternatives," added Dr. Daniel Von Hoff, Cylene's Co-Founder and Vice President, Medical Affairs. "Quarfloxin has demonstrated potent in vivo efficacy agai
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... FRANKLIN, Tenn. , July 27, 2015 ... of health care services and one of the ... announced that its parent company and sole stockholder, ... with Medical Properties Trust, Inc. ("MPT") (NYSE: ... million in cash.  The transaction is expected to be ...
(Date:7/27/2015)... , July 27, 2015   Inocucor Technologies ... sustainable biological accelerators for farmers, has received a ... Trademark Office for its patent application to protect ... plant growth and enhance yields on farms and ... to Inocucor,s live IN-M1 microbial consortium and its ...
(Date:7/27/2015)... Junto Health, a company that helps major ... new technology solutions, today announced the launch of a ... in health care policy consulting. Working together with SPG, ... innovation process while, at the same time, they are ... health care finance and the delivery of health care ...
(Date:7/24/2015)... Ryan & Maniskas, LLP that a class action ... the Northern District of California on ... stock of Avalanche Biotechnologies, Inc. ("Avalanche" or the "Company") (NASDAQ: ... 2015, inclusive (the "Class Period"). Avalanche shareholders may, ... appointment as a lead plaintiff of the Class.  If you ...
Breaking Biology Technology:Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3
... 2009 convention to be held in ... Georgia, ... international convention on June 17 -- 20, in,San Diego, Calif. Governor Perdue will ... convention., "As one of the fastest-growing industries in the nation, the,biosciences sector ...
... June 4 Oramed Pharmaceuticals,Inc. (OTCBB: ORMP.OB) ... delivery,systems, announced today that it has been ... and Pharmacodynamics (PD) of Oral Insulin in,Healthy ... Diabetes,Association,s Scientific Sessions Conference in San Francisco, ...
... to Allow Company to Make Key Marketing Claims, ... Kangtai,Cactus Biotech Inc. (the "Company") (OTC Bulletin Board: ... of a,variety of cactus-based consumer products in China, ... that received the Company,s Cactus,Cattle Feed. The studies, ...
Cached Biology Technology:Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention 2Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention 3Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco) 2Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco) 3China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Company's Cactus Cattle Feed 2China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Company's Cactus Cattle Feed 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... -- Children exposed prenatally to tobacco smoke and during childhood ... to research done at Cincinnati Children,s Hospital Medical Center. ... cases in children between the ages of 8 and 15 ... This could translate into up to 800,000 children ...
... November 23, 2009 Agios Pharmaceuticals today announced that ... the mutated IDH1 gene has a novel enzyme activity ... discovery shows that the mutated form of IDH1 produces ... formation and malignant progression of gliomas, the most common ...
... all read studies about the health benefits of having a ... level, where amino acids known as cysteines are much more ... other cysteines. Now, researchers at the University of Michigan, ... system that protects single cysteines. The research appears in the ...
Cached Biology News:Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4Saving the single cysteine: New antioxidant system found 2
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Biology Products: